Articles

Obinutuzumab plus Bendamustine in Previously Untreated Patients with CLL: Subgroup Analysis of the Phase 3 GREEN Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Phase 2 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Ibrutinib versus Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle-Cell Lymphoma (MCL)

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Syk Inhibitor Entospletinib Monotherapy in CLL/SLL: Phase 2 Trial Results

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Outcomes of Ibrutinib Treatment in Patients with Relapsed or Refractory CLL/SLL with del17p in the RESONATE-17 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Idelalisib plus Bendamustine/Rituximab versus Bendamustine/Rituximab in Relapsed/Refractory CLL: Results of a Phase 3 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Rituximab, Lenalidomide, and Ibrutinib as Frontline Therapy in Follicular Lymphoma: Results of the ALLIANCE 051103 Phase 1 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Patients with Early Breast Cancer and Low Oncotype DX Scores Can Skip Chemotherapy

By Phoebe Starr

Breast Cancer, Solid Tumors

October 2015, Vol 6, No 9

Patients with early breast cancer and a low Oncotype DX recurrence score can safely receive treatment with hormone therapy alone and avoid chemotherapy, according to results of the TAILORx trial, which was sponsored by the National Cancer Institute.

In the Literature - November 2015

In the Literature

November 2015, Vol 6, No 10

80-Gene Assay Identifies Distinct Triple-Positive Breast Cancer Subtypes, Guides Therapy Selection

By Corbin Davis

Breast Cancer, Personalized Medicine, Solid Tumors

November 2015, Vol 6, No 10

San Francisco, CA—A new genetic test may allow clinicians to improve their therapy decisions by better categorizing patients into specific subtypes compared with conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) subtyping. According to data presented at the 2015 Breast Cancer Symposium, the BluePrint 80-gene assay reclassifies approximately 23% of tumors, allowing for more effective therapy selection, particularly in patients with triple-positive (HER2-positive/hormone receptor–positive) disease.

Page 181 of 329